Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service stroke thrombectomy cases in Rhode Island: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (110 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 94 | 51% |
| 2020 | 3 | 73 | 53% |
| 2021 | 4 | 88 | 57% |
Mechanical thrombectomy for acute ischemic stroke. Professional codes (what the surgeon bills): CPT 61645; the hospital bills MS-DRG 023, 024.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Rhode Island; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 30 | 767+7.4%/yr | +7.4%/yr | 0.6 | 0% | 1,030 in 2030+5%/yr |
| New York | 16 | 669 |
Stroke thrombectomy in every state, and its device makers · Every procedure market in Rhode Island · Every state · Compare with Pennsylvania
| ≈ 90 |
| – |
| 2026 est. | ≈ 100 | – |
| 2022 | 4 | 105 | 60% |
| 2023 | 3 | 87 | 64% |
| 2024 | 4 | 113 | 66% |
| 2025 from claims | – | 93 75–109 | 67% |
| 2026 forecast | – | 100 79–126 | 66% |
| 2027 forecast | – | 105 78–139 | 66% |
| 2028 forecast | – | 110 78–152 | 67% |
| 2029 forecast | – | 116 79–166 | 67% |
| 2030 forecast | – | 121 79–180 | 67% |
In 2025, 100% inpatient hospital.
| +0.8%/yr |
| 0.4 |
| 0% |
| 800 in 2030+3%/yr |
| Massachusetts | 15 | 351+2.1%/yr | +2.1%/yr | 0.4 | 0% | 410 in 2030+2.8%/yr |
| New Jersey | 15 | 346+3.2%/yr | +3.2%/yr | 0.3 | 0% | 330 in 2030−1%/yr |
| Connecticut | 7 | 176+8.9%/yr | +8.9%/yr | 0.6 | 0% | 270 in 2030+7.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Endovascular Engineering leads with 40% of company spending on these surgeons in 2025, +40 pts on 2024.
In 2025, 7 companies reported engagement with Rhode Island’s surgeons worth $33K in consulting, speaking, meals and travel tied to these products, about $8,194 per surgeon billing it. Royalties are left out.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.